Redsense holds presentations on Life science-dagen March 4 and Bolagsdagen March 12
In the coming weeks, Redsense Medical AB will present the company and its operations at two occasions. The first presentation will be held on Wednesday March 4, 2020 at Life Science-dagen in Gothenburg, where member of the board and major shareholder Susanne Olausson will give a background to the company and detail its current position in relation to the market, at 14:15. The investor meeting, which features a number of exciting and innovative Life Science and MedTech companies, will take place at the Wallenberg Conference Centre in Gothenburg, located at Medicinareberget in close proximity to the Sahlgrenska Hospital, between 8:00 and 17:30.
For more information about this event, and to register for free, please visit http://www.lifesciencedagen.se/. The program is available here: http://www.lifesciencedagen.se/program-2020.html.
The week thereafter, on Thursday March 12, 2020, Redsense will also participate in the investor meet Bolagsdagen held by Erik Penser Bank at Apelbergsgatan 27 in Stockholm between 10:00 and 16:30. Representatives from 23 companies will attend the event to give presentations of their respective operations during the course of the day; Redsense’s presentation is scheduled for 13:00. To register for this event, please give notice by email to bolagsdagen@penser.se on 9 March at the latest.
Redsense’s product saves lives by detecting blood leakage that occurs in connection with venous needle dislodgement during hemodialysis, a treatment that shows an annual growth rate of about 6 percent globally. The company’s primary market segment, home dialysis and patients at risk, is projected to grow even faster, and a recent analysis by Erik Penser Bank projects that the company will achieve break-even this year. The company further pursues novel applications of its proprietary fiber optics-based technology in the commercially highly interesting segment of Chronic Wound Care, where it has has received a favourable international patent opinion for a smart monitoring system that would provide cost-efficient and personalized treatment of wounds.
“We are experiencing a tremendous growth at the moment, which is primarily driven by the US hemodialysis market and is likely to continue moving forward. With commercial momentum building and technology development surging as well, the company is at a pivotal stage,” says Patrik Byhmer, CEO of Redsense Medical AB: “We want to welcome interested parties to these events, to take the chance to get to know what we fully expect to be one of the future’s household names in the growing fields of hemodialysis and wound care.”
For more information, please contact:
Patrik Byhmer, CEO Redsense Medical AB (publ)
Phone: +46 35 10 60 30
ABOUT REDSENSE MEDICAL
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovationused for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector.